Project/Area Number |
23592141
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Cerebral neurosurgery
|
Research Institution | Keio University |
Principal Investigator |
SASAKI Hikaru 慶應義塾大学, 医学部, 講師 (70245512)
|
Co-Investigator(Kenkyū-buntansha) |
HIROSE Yuichi 藤田保健衛生大学, 医学部, 教授 (60218849)
|
Co-Investigator(Renkei-kenkyūsha) |
YOSHIDA Kazunari 慶應義塾大学, 医学部, 教授 (70166940)
KITAMURA Yohei 慶應義塾大学, 医学部, 助教 (30445382)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | 神経膠腫 / 術前補助療法 / neoadjuvant / 個別化治療 / 化学療法 / 1p19q / MGMT / 脳腫瘍 / 1p/19q / neoadjuvant chemotherapy |
Research Abstract |
We have analyzed 140 WHO grade II-III gliomas by comparative genomic hybridization, and those tumors have been shown to be classified into clinically relevant subgroups based on genetic profiles (gain on 7q vs 1p19q codeletion vs gain of 7/loss of 10q). Molecular genetic analyses of skull base chordomas have revealed that gain on 2p, lack of irradiation, and expression of brachyury (important protein on notochord development) were negatively associated with the risk of recurrence of those tumors. We have shown that molecular-guided upfront chemotherapy, i.e. upfront chemotherapy for gliomas suggested to be chemosensitive based on molecular analyses, could provide, following tumor volume decrease by chemotherapy, chance of radical resection that was not initially possible in significant portion of those tumors. We have also confirmed that combination of tumor calcification and surface tumor localization predicted presence of 1p19q codeletion with high positive predictive value.
|